It may not be one of those hot-shot internet unicorns, but when Kodiak Sciences goes public — possibly next Wednesday — at least one hedge fund firm stands to benefit in a big way.
Joseph Edelman’s Perceptive Advisors is an investor in the development-stage biopharmaceutical company, which on Monday set in motion its initial public offering (IPO), announcing in a new regulatory filing that it plans to offer 9 million shares for between $13 and $15 per share.